secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iris Acquisition Corp (—)
CIK:        0001831874
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001104659-25-003545
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 4.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Iris Acquisition Corp restates Q2 and Q3 2024 financials over undisclosed related party loan
--------------------------------------------------------------------------------

- Determined unaudited financials for June 30, 2024 and Sept 30, 2024 should no longer be relied upon.
- A $1.216M loan from Hana Immunotherapeutics (affiliate of Liminatus Pharma CEO) to fund sponsor managing member acquisition was omitted.
- Loan was a material related party transaction that required disclosure; Audit Committee discussed with auditor Marcum LLP.
- Loan settled on Dec 29, 2024 via delivery of shares in a private Korean company.
- Former managing member Columbass resigned Oct 30, 2024; Iris Equity Holdings appointed as managing member.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831874/000110465925003545/0001104659-25-003545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831874/000110465925003545/tm253036d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-003545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer